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1. Introduction 
The contraction of intestinal muscle evoked by 
prostaglandin E (PGE) can be inhibited by morphine 
[l-3]. Experiments from 2 laboratories using differ- 
ent systems demonstrate that morphine may exert its 
effect by interfering with the stimulation by PGE, of 
the adenylate cyclase system [4-61. Thus, morphine 
inhibits the stimulation by PGEr of the formation of 
adenosine 3’ : 5’cyclic monophosphate (cyclic AMP) 
in rat brain homogenates [4] and in mouse neuro- 
blastoma and mouse neuroblastoma X rat glioma 
hybrid cells [ 5,6]. The specificity of the morphine 
actions is demonstrated by the observation that the 
inhibitory action of morphine can be prevented by 
naloxone [4,6], a morphine analog, known to 
antagonize the action of morphine in vivo [7]. In an 
extension of the studies mentioned above [4,6], the 
work presented here was undertaken in order to answer 
the questions: 1) does morphine interfere with the 
stimulatory effect of PGEi by competing with PGEi 
for the same receptor site? 2) Does morphine exert 
its inhibitory action on all cells in which PGEi 
stimulates the formation of cyclic AMP? 3) Is the 
inhibitory effect of morphine also observed in cells 
in which noradrenaline (NA) is known to increase the 
intracellular levels of cyclic AMP? The concentration of 
cyclic AMP in the 3 cell types used for their study is 
enhanced by different neurohormones: By PGEr in 
a mouse neuroblastoma line [8,9], by PGEi [lo] or 
NA [ 11,121 in a rat glioma line and by PGEr or NA 
in a rat glioma X mouse fibroblast line [lo]. 
Our results show that the inhibitory action of 
morphine cannot be overcome by high concentrations 
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of PGEi , thus demonstrating that PGEr and mor- 
phine must act at different receptor sites. Furtheron, 
the inhibitory effect of morphine is not found in all 
cell lines, in which PGEr stimulates the formation of 
cyclic AMP; and it is not observed in 2 cell lines the 
cyclic AMP level of which is increased in the presence 
of NA. The results indicate that the antagonistic 
action of morphine may be restricted as to the cell 
type and hormone affected. This study provides 
further evidence for the usefulness of cell cultures as 
model systems for studying drug action. 
2. Methods 
2.1. Cell culture 
All cells used are clonal lines. Line N4TG3 is a 
6-thioguanine resistant mutant [ 131 of line N4 [ 141 
derived from mouse neuroblastoma C- 1300, C6-BU-1 
a bromodeoxyuridine resistant line [ 131 derived from 
rat glioma line C6 [ 151. 54SCCll is a hybrid line 
obtained by fusion of C6-BU-1 and the 6-thioguanine 
resistant mouse tibroblast line A9 [ 10,161. The cells 
are routinely cultured in plastic petri dishes 10 cm in 
diameter (Greiner, Ntirtingen) [lo]. 
2.2. Experimental incubation 
The experimental incubation is essentially as describ- 
ed [ 171. Briefly, after removal of the growth medium, 
the cells are washed once with 5 ml incubation 
medium [ 171. Subsequently, 5 ml of incubation 
medium (37”C, pH 7.4) is added, followed by 50 ~1 
1 mM PGEr in 96% ethanol and 50 ~1 of Dulbecco’s 
modified Eagle’s medium containing varying concen- 
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trations of morphine hydrochloride (Boehringer, Ingel 
heim). The controls receive the same volumes of pure 
solvents. The plates are incubated for 10 min at 37°C 
as described [ 171. At the end of the incubation, 
medium and cells are separately assayed for cyclic 
AMP [ 171 using a protein binding assay [ 181. In all 
cases, the amount of cyclic AMP released from the 
cells into the medium during experimental incubation 
was less than 10% of the total cyclic AMP in cells 
plus medium. Therefore, all data given are only those 
for the intracellular content of cyclic AMP. 
3. Results and discussion 
As reported 161, in neuroblastoma and neuro- 
blastoma X glioma hybrid cells morphine inhibits the 
increase of intracellular cyclic AMP observed in the 
presence of PGEr . In order to answer the question 
whether or not PGEr and morphine compete for the 
same receptor site, neuroblastoma cells were incubated 
with increasing concentrations of PGEr in the 
presence or absence of morphine. Fig. 1 illustrates 
that even at concentrations of 30 E.~M (more than 300 
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Fig. 1. Formation of cyclic AMP in presence of PGE, or PGE, 
and morphine as a function of the concentration of PGE, . 
19.4 million viable N4TG3 cells per plate, viability 99%; 
passage number 37; I: Absence of morphine; II: Presence of 
30 PM morphine. 
times the dose at which PGEr elevates cyclic AMP to 
half maximal value) PGEr does not reverse the effect 
of morphine. Thus, the data are suggestive of a non- 
competitive type of inhibition and consequently of 
different. binding sites for PGE, and morphine. This 
result is in contrast to the report by Collier and Roy 
[4], who found decreased inhibition by morphine with 
increased PGEr concentration. However, the dis- 
crepancy may be only apparent, since their system is 
rather insensitive to PGEr . From their data one can 
calculate that it is at PGE, concentrations between 
8.8 and 88 PM that they find a major increase in 
formation of cyclic AMP with increased concentration 
of PGEr . Now, when they increase the PGEr concen- 
tration from 8.8 to 177 PM in the presence of morphinc 
they find a mean reduction of the inhibition caused 
by morphine from 39 to 18%. This is what one would 
expect for a system of noncompetitive inhibition, if 
one enhances the reaction rate by increasing the 
-z- I 1 I 7 6 5 I. 3 
-log [morphme] 
Fig. 2. Morphine and the stimulation by PGE, and NA of 
intracellular cyclic AMP in glioma line C6-BU-1 and glioma 
X fibroblast hybrid line 54SCCll. C6-BU-1: Passage 3 1, 5 1.4 
- million viable cells per plate, viability 100%. 54SCCll: 
passage 6, 6 million viable cells per plate, viability 94%. I: 
54SCCl1, no hormones; II: 54SCC11, 0.1 mM NA; III: 
CCBU-1, no hormones; IV: 54SCCl1, 3 PM PCE, ; V: 
CCBU-1, 10 crM PGE, ; VI and VII: C6-BU-1, 1 and 100 PM 
NA, respectively. 
261 
Volume 49, number 2 FEBS LETTERS December 1974 
saturation of receptors with agonist molecules, while 
keeping the concentration of antagonist constant. 
Inserting their data [4] into the formulae for non- 
competitive inhibition [ 191, one can compute a curve 
resembling the one in fig. 2 of ref. [4]. The low 
sensitivity to PGEr of the brain homogenates [4] 
reflects probably a damaging influence of the 
homogenization procedure on the PGEr receptors. 
In most respects, rat glioma line C6-BU-1 [ 131 
behaves very similar to the wild type line C6 [ 1.51. 
Both, C6 [ 1 l] and C6-BU-1 [ 10,121 increase their 
intracellular levels of cyclic AMP in the presence of 
NA. C6-BU-1 does so also when exposed to PGEr 
[lo]. Similarly, the clonal hybrid line 54SCC11, 
obtained by fusion of C6-BU-1 with mutant mouse 
fibroblast line A9, is sensitive to both NA and PGEr 
[lo]. Thus, C6-BU-1 and 54SCCll cells are well suited 
to serve in finding answers to the following questions: 
1) does morphine only antagonizes the action of PGEr 
in cells of neuronal origin or character? 2)Does it also 
antagonize neurohormones other than PGEr that 
stimulate formation of cyclic AMP? Morphine alone 
does not appreciably affect the levels of cyclic AMP 
in lines C6-BU-1 and 54SCCll (fig. 2, curves I and 
III). It does neither antagonize the stimulatory action 
of PGEr on 54SCCll (curve IV) and C6-BU-I (curve 
V) nor of NA on 54SCCll (curve II) and C6-BU-1 
(curves VI and VII). That the stimulation of these 
cells by NA is susceptible to inhibition by a suitable 
substance isdemonstrated in table 1. In both cell 
lines propranolol, a S-adrenergic blocking agent, com- 
pletely prevents the increase of the intracellular level 
of cyclic AMP evoked by NA. Thus, in both cell lines 
neither the stimulation of cyclic AMP formation by 
PGEr nor that by NA is antagonized by morphine. 
These results demonstrate hat morphine does not 
interfere with the action of PGEr on all types of cells. 
In fact, the data suggest that susceptibility to morphine 
exists only in certain cell types and that nerve cells, 
but probably not glial cells, may be among them. How- 
ever, our data do not contribute to answering the 
questions: a) are all nerve cells sensitive to PGEr also 
susceptible to morphine? b) Are all glial cells sensitive 
to PGEr insensitive to morphine? c) Are there cells, 
in which morphine antagonizes the stimulatory effect 
of NA or other hormones known to act via cyclic 
nucleotides as second messengers? In other words is 
PGEr the only hormone antagonized by morphine? 
Are there cases, in which prostaglandins other than 
PGEr are antagonized by the narcotic? It is tempting 
to assume that cells insensitive to morphine are lacking 
an ‘opiate receptor’. Presently we are testing this 
hypothesis. Question a) might be answered tenta- 
tively. While opiate receptors are abundant in the 
limbic system, they are hardly detectable in other 
areas of the brain [20-221. Provided that nerve cells 
in regions devoid of opiate receptors are responsive to 
PGEr , question a) must be answered negatively. 
Table 1 
The p-adrenergic antagonist propranolol inhibits the increase of the concentration 
of intracellular cyclic AMP elicited by NA. Glioma cells and glioma X 
tibroblast hybrid cells are studied. The experimental incubations 
are analogous to those described in Methods. 
cell line 
concentration of additions OcM) 
NA propranolol 
cyclic AMP 
(pmol/mg protein) 
glioma CCBU-1 0 
0 
1 
100 
100 
glioma X tibroblast 0 
hybrid 54SCCll 0 
100 
100 
0 12 f 2* 
200 10.0 * 1.7 
0 3100 * 40 
0 6500 r 600 
200 13.2 + 1.6 
0 9.3 f 2.1 
100 10.0 f 1.0 
0 19.3 f 2.2 
100 8.9 f 0.7 
* Standard deviation 
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